<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5609">
  <stage>Registered</stage>
  <submitdate>9/01/2012</submitdate>
  <approvaldate>9/01/2012</approvaldate>
  <nctid>NCT01508806</nctid>
  <trial_identification>
    <studytitle>Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function</studytitle>
    <scientifictitle>A Single-centre, Open-label, Trial Investigating the Pharmacokinetics and the Tolerability of Liraglutide in Subjects With Normal Renal Function and in Subjects With Impaired Renal Function</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NN2211-1329</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes</healthcondition>
    <healthcondition>Diabetes Mellitus, Type 2</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - liraglutide

Experimental: Normal renal function - 

Experimental: Mild renal impairment - 

Experimental: Moderate renal impairment - 

Experimental: Severe renal impairment - 

Experimental: End-stage renal disease - 


Treatment: drugs: liraglutide
Single dose of 0.75 mg, administered as a subcutaneous injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Area under the Curve (AUC)</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>AUC (0-t)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cmax, maximum concentration</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>tmax, time to reach Cmax</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>tÂ½, terminal half-life</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>CLR (renal clearance)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects meeting the pre-defined GFR (glomerular filtration rate) criteria (estimated
             by the Cockcroft and Gault formula) for any of the renal function groups

          -  Body Mass Index (BMI) maximum 40 kg/m^2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known or suspected allergy to trial product(s) or related products

          -  Renal transplanted patients

          -  Haemodialysis patients

          -  Cardiac problems

          -  Uncontrolled treated/untreated hypertension

          -  History of alcoholism or drug abuse during the last 12 months

          -  Smoking of more than 10 cigarettes per day, or the equivalent for other tobacco
             products

          -  Habitual excessive consumption of methylxanthine-containing beverages and foods
             (coffee, tea, soft drinks such as cola, chocolate) as judged by the investigator

          -  Excessive consumption of food deviating from a normal diet as judged by the
             Investigator</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>30</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Novo Nordisk Investigational Site - Christchurch</hospital>
    <postcode>2856 - Christchurch</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novo Nordisk A/S</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial is conducted in Oceania. The aim of this trial is to assess whether dose
      adjustment is required for patients with renal impairment by investigating the
      pharmacokinetics of liraglutide in subjects with various degrees of renal impairment.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01508806</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Global Clinical Registry (GCR, 1452)</name>
      <address>Novo Nordisk A/S</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>